Johnson & Johnson unveiled financial results that beat Wall Street expectations as the company braces for one of its ...

Johnson & Johnson (JNJ) beat on fourth quarter and full-year 2024 results, but its stock traded down on Wednesday morning to ...

JNJ stock reporting earnings, expecting $2 EPS and $22.44B revenue, approval for Spravato, mixed chart signals, $167.71 price ...

Analysts on Wall Street project that Johnson & Johnson (JNJ) will announce quarterly earnings of $2 per share in its forthcoming report, representing a decline of 12.7% year over year. Revenues ...

Johnson & Johnson's Q4 2024 earnings missed EPS expectations, but broadly met revenue targets. Click here to read why JNJ ...

Pharma giant Johnson & Johnson is buying Intra-Cellular Therapies, eying sales growth above analysts’ expectations through ...

Wall Street indexes hit new highs, driven by optimism in tech stocks, following President Trump's announcement of a $500 ...

Johnson & Johnson expects full-year earnings in the range of $10.50 to $10.70 per share, with revenue in the range of $89.2 billion to $90 billion. This story was generated by Automated Insights ( ...

Johnson & Johnson (JNJ – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Tim ...